FDA OKs Takeda, Protagonist drug for rare blood cancer
BioPharma Dive
The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.
pharminent
August 31, 2026 (Last updated: September 7, 2026)
BioPharma Dive
The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.